Hong Kong Insurance Stock News

With inflation trends uneven across regions and central banks sending mixed signals on rate paths, dependable income can feel hard to find. That is where the Dividend Powerhouses screener comes in, focusing on companies with dividend yields above 5% that are covered by current earnings, growing and relatively stable. While policy debates continue around interest rates, growth and inflation, these stocks aim to put cash in your account today. In this article, you will see three stocks from the...

Shanghai MicroPort MedBot (Group) (SEHK:2252) is in focus after its Toumai Remote laparoscopic surgery robot received the EU CE Mark, opening access to more than 30 European markets and providing formal regulatory recognition of remote surgery. See our latest analysis for Shanghai MicroPort MedBot (Group). The Toumai Remote CE Mark news comes as Shanghai MicroPort MedBot (Group)'s 1 day share price return of 1.57% and 7 day share price return of 4.20% contrast with weaker 30 and 90 day share...

Insiders were net sellers of Onewo Inc.'s ( HKG:2602 ) stock during the past year. That is, insiders sold more stock...

Xiamen Yan Palace Bird's Nest Industry Co., Ltd. ( HKG:1497 ), is not the largest company out there, but it saw a...

The fact that multiple SITC International Holdings Company Limited ( HKG:1308 ) insiders offloaded a considerable...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Whilst it may not be a huge deal, we thought it was good to see that the Starjoy Wellness and Travel Company Limited...

Those following along with China Wantian Holdings Limited ( HKG:1854 ) will no doubt be intrigued by the recent...

Man Wah Holdings Limited ( HKG:1999 ) stock is about to trade ex-dividend in 4 days. The ex-dividend date generally...

As global markets navigate a complex landscape marked by mixed performances in major indices and economic data, investors are increasingly turning their attention to Asia, where resilient manufacturing activity and strategic policy measures are shaping the investment climate. In this context, identifying undervalued stocks that trade below their estimated fair value can offer opportunities for those seeking to capitalize on potential market inefficiencies.

It's been a mediocre week for Want Want China Holdings Limited ( HKG:151 ) shareholders, with the stock dropping 17% to...

As Asian markets navigate a mixed landscape with resilient manufacturing activity in China and shifting sentiment in Japan, investors are keenly observing opportunities that may arise. Penny stocks, though often overlooked, present unique prospects for those seeking growth potential within smaller or newer companies. Despite their traditional reputation as speculative investments, some penny stocks demonstrate robust financial health and can offer intriguing opportunities for long-term success.

China Life Insurance (SEHK:2628) has approved a final dividend of RMB 0.618 per share, equivalent to HK$0.71060, at its 25 June 2026 AGM, giving investors clearer visibility on upcoming income. See our latest analysis for China Life Insurance. The dividend decision comes after a mixed stretch for China Life Insurance’s share price, with a 12.32% 90 day share price return but a year to date share price return that is down 2.64%. At the same time, the 1 year total shareholder return of 57.67%...

Sino Biopharmaceutical (SEHK:1177) is back in focus after China’s regulators approved Peceleganan Spray and accepted a new drug application for tecotabart vedotin, LM-302. These are two pipeline milestones in infection control and advanced gastric cancer. See our latest analysis for Sino Biopharmaceutical. Despite the drug pipeline progress, Sino Biopharmaceutical’s share price tells a mixed story. The HK$4.62 close reflects a 1-day share price return of 4.76% and a 7-day gain of 8.45%, set...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn investor attention after new translational research on its sac-TMT and osimertinib combination for EGFR-mutant non small cell lung cancer was published in the journal Cancer Cell. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The latest Cancer Cell publication and wider sac-TMT trial updates arrive as Sichuan Kelun-Biotech Biopharmaceutical trades at HK$467.6, with a year to date share price return of 16.72%...

Baijin Life Science Holdings (SEHK:1466) has posted its latest full year update with first half FY 2026 revenue of HK$55.1 million and EPS of HK$0.0028, while trailing twelve month figures show revenue of HK$89.3 million and EPS of HK$0.0449 loss alongside a net loss of HK$37.9 million. The company has seen recent half year revenue move from HK$70.9 million in 1H FY 2025 to HK$64.7 million in 2H FY 2025 and HK$55.1 million in 1H FY 2026, with EPS shifting from a HK$0.0092 loss to HK$0.0083...

What the 5-year China Government Bond Futures Launch Means for HKEX Hong Kong Exchanges and Clearing (SEHK:388) is in focus after regulators set a target launch date of 3 August 2026 for 5-year China Government Bond Futures in Hong Kong, expanding the exchange's fixed-income toolkit. This planned contract sits alongside Stock Connect, Bond Connect, Swap Connect and MSCI China A50 Connect Index Futures. It gives investors in Chinese bonds another way to manage interest rate risk linked to...

China Galaxy Securities (SEHK:6881) has drawn investor attention after its 2025 Annual General Meeting approved a final cash dividend. The ex-dividend, record and payment dates are now set for July and August 2026. See our latest analysis for China Galaxy Securities. The share price of China Galaxy Securities has come under pressure recently, with a year to date share price return down 28.95% and a 30 day share price return down 6.68%, even though the 3 year total shareholder return is up...

GoFintech Quantum Innovation (SEHK:290) has put fresh numbers on the table for FY 2026, with first half revenue of HK$1.0b and basic EPS of HK$0.029 setting the tone for how the year is shaping up. The company has seen revenue move from HK$21.3m in the first half of 2025 to HK$838.9m in the second half of 2025 and then to HK$1.0b in the first half of 2026. Basic EPS has shifted from a loss of HK$0.0017 to a small profit of HK$0.0012 and then HK$0.029 across the same periods, giving investors...

ZXZN Qi-House Holdings (SEHK:8395) has reported its FY 2026 first half results with revenue of HK$67.2 million and basic EPS of HK$0.00002, setting a cautious tone around earnings quality and profitability. The company has seen first half revenue move from HK$34.8 million in 2024 to HK$38.5 million in 2025 and now HK$67.2 million in 2026. At the same time, EPS has shifted from a loss of HK$0.00806 per share in 2024 to a smaller loss of HK$0.00055 in 2025 and a near flat HK$0.00002 in 2026...

Seven Elements Investment Holdings (SEHK:1660) has reported its FY 2026 first half results with revenue of HK$84.6 million and basic EPS of HK$0.000063, setting a cautious tone for investors tracking its profitability. The company has seen revenue move from HK$110.8 million in the first half of FY 2025 to HK$87.1 million in the second half of FY 2025 and HK$84.6 million in the latest half. Net income shifted from a loss of HK$7.4 million and HK$70.4 million in those prior halves to a profit...

Canadian denosumab launch puts Shanghai Henlius Biotech in focus Shanghai Henlius Biotech (SEHK:2696) is drawing attention after announcing that its denosumab biosimilars BILDYOS and TUZEMTY are now available in Canada through partner Organon, covering all indications of the reference products. The launch extends Henlius’s reach beyond its primarily China based revenue by bringing its osteoporosis and oncology supportive care portfolio into a mature biologics market, where Organon holds...

L.K. Technology Holdings (SEHK:558) has just reported FY 2026 first half results, with revenue of HK$3.3 billion and basic EPS of HK$0.10, setting the tone for how investors gauge the latest move in profitability. The company has seen revenue shift from HK$2,594.4 million in the first half of FY 2025 to HK$3,230.5 million in the second half and now HK$3,260.5 million in the latest half, while basic EPS has moved from HK$0.11 to HK$0.15 and now HK$0.10. The market is left to weigh upbeat...

China HK Power Smart Energy Group (SEHK:931) has reported its FY 2026 first half with revenue of HK$253.1 million and a basic EPS loss of HK$0.010, while trailing twelve month figures show revenue of HK$814.7 million and a basic EPS loss of HK$0.023 as the stock trades around HK$0.30. Over the past three reported half year periods, the company has seen revenue move from HK$252.8 million in 1H FY 2025 to HK$460.7 million in 2H FY 2025 and HK$253.1 million in 1H FY 2026, alongside basic EPS...